SRPT - Sarepta Therapeutics, Inc. -  [ ]

Seasonality of Returns By Period

Average daily return by calendar bucket (ClosePriceSA).

Day of Week

Week of Month

Month of Year

Seasonal Path

YTD vs Last Year vs Lookback Avg ยท closes rebased to 100 at each year's first session
Ticker Details
Sarepta Therapeutics, Inc.
Sarepta Therapeutics Inc is a biotechnology company. It uses proprietary RNA-targeted technology platforms for developing pharmaceutical products to address serious diseases.
IPO Date: July 12, 2012
Sector: Healthcare
Industry: Biotech
Market Cap: $1.85B
Activated in VL: True
Average Daily Range
Avg Daily Range: $1.74 | 2.95%
Avg Daily Range (30 D): $0.68 | 3.37%
Avg Daily Range (90 D): $0.53 | 2.91%
Institutional Daily Volume
Avg Daily Volume: 1.87M
Avg Daily Volume (30 D): 2.49M
Avg Daily Volume (90 D): 2.47M
Trade Size
Avg Trade Size (Sh.): 104
Avg Trade Size (Sh.) (30 D): 75
Avg Trade Size (Sh.) (90 D): 71
Institutional Trades
Total Institutional Trades: 14,331
Avg Institutional Trade: $4.05M
Avg Institutional Trade (30 D): $4.35M
Avg Institutional Trade (90 D): $5.27M
Avg Institutional Trade Volume: .06M
Avg Institutional Trades (Per Day): 4
Market Closing Trades
Avg Closing Trade: $8.78M
Avg Closing Trade (30 D): $9.82M
Avg Closing Trade (90 D): $10.4M
Avg Closing Volume: 142.53K
 
News
Oct 6, 2026 @ 7:51 PM
Top Research Reports for SpaceX, Dell & KLA Corp.
Source: Mark Vickery
Sep 15, 2026 @ 9:58 AM
Oligonucleotide Therapeutics Market Outlook 2026-2...
Source: Researchandmarkets.Com
Jul 11, 2026 @ 8:30 PM
2 Beaten-Down Stocks That Still Aren't Worth Buyin...
Source: Prosper Junior Bakiny
May 20, 2026 @ 3:15 PM
My Top 3 Biotech Stocks for May 2026
Source: Jeff Siegel
May 18, 2026 @ 6:33 PM
Protein Synthesis Research Market to Reach $42.8 B...
Source: Bcc Research
Financials
  TTM Q2 2026 Q1 2026
Basic EPS $-1.33 $-.05 $3.15
Diluted EPS $-1.44 $-.05 $2.88
Revenue $1.97B $401.25M $730.8M
Gross Profit
Net Income / Loss $-136.73M $-4.89M $330.96M
Operating Income / Loss $-143.25M $13.29M $358.43M
Cost of Revenue
Net Cash Flow $55.1M $103.7M $-336.83M
PE Ratio    
Splits
Jul 12, 2012 1:6